Clinical Trials · NCT04649580

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Name: United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedN/ALanreotide

Phase: N/A
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 80
Start date: Apr 2021
Locations: 5 sites, United Kingdom
Primary endpoint: Patient preferences of treatment administration setting (homecare or hospital)

View Lanreotide compound reference